Risk Factors for Incident Diabetic Polyneuropathy in a Cohort With Screen-Detected Type 2 Diabetes Followed for 13 Years: ADDITION-Denmark
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To study incident diabetic polyneuropathy (DPN) prospectively during the first 13 years after a screening-based diagnosis of type 2 diabetes and determine the associated risk factors for the development of DPN. RESEARCH DESIGN AND METHODS: We assessed DPN longitudinally in the Danish arm of the Anglo-Danish-Dutch study of Intensive Treatment of Diabetes in Primary Care (ADDITION) using the Michigan Neuropathy Screening Instrument questionnaire (MNSIQ), defining DPN with scores ≥4. Risk factors present at the diabetes diagnosis associated with the risk of incident DPN were estimated using Cox proportional hazard models adjusted for trial randomization group, sex, and age. RESULTS: Of the total cohort of 1,533 people, 1,445 completed the MNSIQ at baseline and 189 (13.1%) had DPN at baseline. The remaining 1,256 without DPN entered this study (median age 60.8 years [interquartile range 55.6; 65.6], 59% of whom were men). The cumulative incidence of DPN was 10% during 13 years of diabetes. Age (hazard ratio [HR] 1.03 [95% CI 1.00; 1.07]) (unit = 1 year), weight (HR 1.09 [95% CI 1.03; 1.16]) (unit = 5 kg), waist circumference (HR 1.14 [95% CI 1.05; 1.24]) (unit = 5 cm), BMI (HR 1.14 [95% CI 1.06; 1.23]) (unit = 2 kg/m2), log2 methylglyoxal (HR 1.45 [95% CI 1.12; 1.89]) (unit = doubling), HDL cholesterol (HR 0.82 [95% CI 0.69; 0.99]) (unit = 0.25 mmol/L), and LDL cholesterol (HR 0.92 [95% CI 0.86; 0.98]) (unit = 0.25 mmol/L) at baseline were significantly associated with the risk of incident DPN. CONCLUSIONS: This study provides further epidemiological evidence for obesity as a risk factor for DPN. Moreover, low HDL cholesterol levels and higher levels of methylglyoxal, a marker of dicarbonyl stress, are identified as risk factors for the development of DPN.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Neuropathic pain can lead to interference with daily activities, disability, psychosocial impairment, and reduced health-related QoL.547,552,562,563”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [547]
In the citing paper
“The earliest affected nerve fibers are usually the small myelinated and unmyelinated fibers; thus, the most common early symptoms are pain and dysesthesias (unpleasant sensations of burning).547,554,555”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [547]
In the citing paper
“Characteristically, the pain is burning, lancinating, tingling, or shooting (electric shock-like), with paresthesia, occurring in varying combinations, and is typically worse at night547”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [547]
In the citing paper
“However, the presence of atypical features including motor deficits greater than sensory, asymmetry of symptoms and signs, and rapid progression warrant a timely referral.547”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [547]
In the citing paper
“A combination of typical symptomatology and symmetrical distal sensory loss, or typical signs in the absence of symptoms, in a person with DM is highly suggestive of DPN and may not require additional evaluations or referral.547,565–567”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [547]
37 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690
Diabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602 · cited 2×
“DPN increases the risk of chronic pain, falls, foot ulcers, and amputations; it also negatively affects the quality of life (3).”
BackgroundResultSelf-citationDyck, P. J., Kratz, K. M., Karnes, J. L., Litchy, W. J., Klein, R., Pach, J. M., Wilson, D. M., O'Brien, P. C., & Melton, L. J. (1993) · Neurology · doi:10.1212/wnl.43.4.817 · Cited by 1,482 · cited 1×
“Of these, diabetic polyneuropathy (DPN) is the most common complication (2).”
BackgroundVascular risk factors and diabetic neuropathy
Tesfaye, S., Chaturvedi, N., Eaton, S. E. M., Ward, J. D., Manes, C., Ionescu-Tirgoviste, C., Witte, D. R., & Fuller, J. H. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa032782 · Cited by 1,323
Self-citationFeldman, E. L., Stevens, M. J., Thomas, P. K., Brown, M. B., Canal, N., & Greene, D. A. (1994) · Diabetes Care · doi:10.2337/diacare.17.11.1281 · Cited by 1,293
Self-citationDiabetic neuropathy: clinical manifestations and current treatments
Callaghan, B. C., Cheng, H. T., Stables, C. L., Smith, A. L., & Feldman, E. L. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70065-0 · Cited by 1,211
Self-citationThe global burden of diabetes and its complications: an emerging pandemic
Susan van, D., Beulens, J. W. J., Yvonne T. van der, S., Grobbee, D. E., & Nealb, B. (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000368191.86614.5a · Cited by 874 · cited 2×
“patients with diabetes over the course of their lives (1,4,5).”
BackgroundAdvances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy
Tesfaye, S., & Selvarajah, D. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2239 · Cited by 615 · cited 1×
“Other metabolic syndrome components such as obesity, hypertension, low HDL cholesterol, and hypertriglyceridemia are among the potential additional risk factors for the development of DPN (6,8,10).”
Background
Cited by
Items 101–200 of 257
Ponirakis, G., Al‐Janahi, I., Elgassim, E., Gad, H., Petropoulos, I. N., Khan, A., Ali, H. A., Siddique, M. A., Gul, W., Ferdousi, M., et al. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13864 · Cited by 19
“Similarly, in a longitudinal study of 1,256 patients with type 2 diabetes followed over 13 years, Andersen et al.8 showed that weight, BMI, waist circumference, HDL, and LDL were associated with incident DPN. We44 and others3 have shown that systolic blood pressure was independently associated with DPN.”
BackgroundHukportie, D. N., Li, F., Zhou, R., Zheng, J., Wu, X., Zou, M., & Wu, X. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13273 · Cited by 20
“38–41 In a 13-year follow-up longitudinal study of 1533 diabetic patients, the authors found lower levels of HDL and LDL to be significantly associated with a higher risk of polyneuropathy.(42) Because abnormal levels of lipid profile may be indicative of instability in lipid control (dyslipidemia), a similar deleteri…”
BackgroundDiabetic peripheral neuropathy: age-stratified glycemic control
Wang, C.-S., Pai, Y., Lin, C., Lee, I., Chen, H.-H., & Chang, M. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1377923 · Cited by 24
“DPN contributes to numerous disabling morbidities, and DPN-related diabetic foot ulcerations are the most common cause of non-traumatic lower-limb amputations in most high-income countries (2, 3).”
BackgroundZhang, Y., Wu, X., Yao, W., Ni, Y., & Ding, X. (2024) · Pharmaceutical Biology · doi:10.1080/13880209.2024.2369301 · Cited by 18
“Dyslipidemia is a key factor in neuropathy development (Andersen et al. 2018), and lifestyle interventions such as weight loss and physical activity have shown positive effects in DPN management, rather than conventional lipid-lowering medications (Afshinnia et al. 2022).”
BackgroundPrediction of Diabetic Sensorimotor Polyneuropathy Using Machine Learning Techniques
Shin, D. Y., Lee, B., Yoo, W. S., Park, J. W., & Hyun, J. K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194576 · Cited by 18
Lipid Levels and Risk of Diabetic Polyneuropathy in 2 Danish Type 2 Diabetes Cohorts
Kristensen, F., Christensen, D. H., Callaghan, B. C., Nielsen, J. S., Højlund, K., Andersen, H., Dekkers, O. M., Groenwold, R. H. H., Sørensen, H. T., & Thomsen, R. W. (2024) · Neurology · doi:10.1212/wnl.0000000000209538 · Cited by 20
Self-citationInflammatory Markers and Measures of Cardiovascular Autonomic Neuropathy in Type 1 Diabetes
Ang, L. P., GUNARATNAM, S. V. G., Huang, Y., Dillon, B. R., Martin, C. L., Burant, A., Reiss, J., Blakely, P. K., Vasbinder, A. L., Zhao, L., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.036787 · Cited by 18
Self-citationGlycemic Targets and Prevention of Complications
Tsushima, Y., & Galloway, N. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae776 · Cited by 21
Shared decision making, diagnostic evaluation, and pharmacotherapy in type 2 diabetes
Brockamp, C., Landgraf, R., Müller, U. A., Müller‐Wieland, D., Petrak, F., & Uebel, T. (2023) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2023.0219 · Cited by 25
The metabolic drivers of neuropathy in India
Reynolds, E. L., Callaghan, B. C., Banerjee, M., Feldman, E. L., & Viswanathan, V. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107653 · Cited by 15
Self-citationMaiga, Y. M., Diallo, S., Konipo, F. D. N., Sangho, O., Sangaré, M., Diallo, S. H., Saliou, M., Péréon, Y., Giumelli, B., Coulibaly, A., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241387 · Cited by 20
“These patients can potentially develop irreversible neurological damage that leads to amputation of the affected limbs [53].”
BackgroundSystems Biology to Address Unmet Medical Needs in Neurological Disorders
Savelieff, M. G., Noureldein, M. H., & Feldman, E. L. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2265-0_13 · Cited by 15
Self-citationAdvances in diagnosis and management of distal sensory polyneuropathies
Silsby, M., Feldman, E. L., Dortch, R. D., Roth, A. R., Haroutounian, S., Rajabally, Y. A., Vucic, S., Shy, M. E., Oaklander, A. L., & Simon, N. G. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-328489 · Cited by 15
Self-citationNeuropathy and the metabolic syndrome
Piccolo, N., Wiggers, A., Koubek, E. J., & Feldman, E. L. (2024) · eNeurologicalSci · doi:10.1016/j.ensci.2024.100542 · Cited by 15
Self-citationHaque, F., Reaz, M. B. I., Chowdhury, M. E. H., Ali, S. H. M., Bakar, A. A. A., Rahman, T., Kobashi, S., Dhawale, C. A., & Bhuiyan, M. A. S. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104954 · Cited by 15
Herder, C., Zhang, S., Wolf, K., Maalmi, H., Bönhof, G. J., Rathmann, W., Schwettmann, L., Thorand, B., Roden, M., Schneider, A., et al. (2023) · Science of The Total Environment · doi:10.1016/j.scitotenv.2022.159878 · Cited by 11
“The observed effect size for the combined exposures to several environmental risk factors is in the same range as those for established anthropometric and metabolic risk factors of DSPN (Andersen et al., 2018; Schlesinger et al., 2019).”
BackgroundThe Role of Protein Adduction in Toxic Neuropathies of Exogenous and Endogenous Origin
Spencer, P. S., & Chen, X. (2021) · Toxics · doi:10.3390/toxics9050098 · Cited by 13
Cho, N. R., Yu, Y., Oh, C., Ko, D. S., Myung, K., Lee, Y., Na, H. S., & Kim, Y. H. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223211041936 · Cited by 13
Dantas, J. M., Oliveira, M. D. J., Silva, L. A. O., Batista, S., Dagostin, C. S., & Schachter, D. C. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01318-y · Cited by 14
“Factors associated with the development of painful diabetic peripheral neuropathy (pDPN) include smoking, age, stature, duration of diabetes, type 2 diabetes, HbA1c, and metabolic syndrome components [6], especially obesity [7].”
BackgroundRisk Factors for Developing Diabetic Peripheral Neuropathy: a Meta-analysis
Fakkel, T. M., Çakici, N., Coert, J. H., Verhagen, A. P., Bramer, W. M., & van Neck, J. W. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00480-0 · Cited by 15
“Previous studies have identified poor glycaemic control as a major risk factor for the development of DPN [7, 10, 11, 15, 16].”
BackgroundThe determinants of complication trajectories in American Indians with type 2 diabetes
Reynolds, E. L., Akıncı, G., Banerjee, M., Looker, H. C., Patterson, A., Nelson, R. G., Feldman, E. L., & Callaghan, B. C. (2021) · JCI Insight · doi:10.1172/jci.insight.146849 · Cited by 12
Self-citationSingleton, J. R., Foster-Palmer, S. C., & Marcus, R. L. (2021) · Current Diabetes Reviews · doi:10.2174/1573399817666210923125832 · Cited by 15
Wang, C.-S., Pai, Y., Lin, C., Lee, I., & Chang, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-09333-3 · Cited by 17
Risk Factors for Subclinical Diabetic Peripheral Neuropathy in Type 2 Diabetes Mellitus
Gao, L., Qin, J., Chen, Y., Jiang, W., Zhu, D., Zhou, X., Ding, J., Qiu, H., Zhou, Y., Dong, Q., et al. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s433024 · Cited by 17
“…HbA1c level, dyslipidemia, and existence of comorbidities, including hypertension, cardiovascular disease, and kidney disease are widely reported as risk factors of DPN. 2,8,18 Some studies observed that NLR and hypoglycemic episodes showed significant independent associations with DPN in T2DM.”
BackgroundKural, M. A., Andersen, S. T., Andersen, N. T., Andersen, H., Charles, M., Finnerup, N. B., Jensen, T. S., & Tankişi, H. (2018) · Muscle & Nerve · doi:10.1002/mus.26361 · Cited by 12
“tion carried out at 5 study sites between 2015 and 2016, that is, 13 years after the trial baseline.(12,13) Two hundred Abbreviations: ADDITION, Anglo-Danish-Dutch study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (trial); AUC, area under the curve; CV, conduction velocity; DPN, diab…”
MethodSelf-citationAdvances in the pathophysiology and treatment of diabetic peripheral neuropathy
Fridman, V., Elafros, M. A., Eid, S., Reynolds, E. L., McCray, B. A., & Callaghan, B. C. (2026) · BMJ · doi:10.1136/bmj-2024-081217 · Cited by 16
“…of DPN. 41 59 By contrast, the ADDITION-Denmark and DD2 studies did not find hypertension or blood pressure to increase the likelihood of DPN. 43 44 For people with type 1 diabetes, both the EURODIAB and SEARCH studies found that hypertension increased the likelihood of having DPN. 16 47 58…”
Self-citationJude, E. B., Siafarikas, C., Rastogi, A., Bém, R., Tankova, T. I., Kong, M., LaFontaine, J., Pappachan, J. M., & Tentolouris, N. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/4275741 · Cited by 12
Brock, C., Andersen, H., Alibegovic, A. C., Andersen, S. R. D., Andreasen, L., Charles, M., Christensen, D. H., Drewes, A. M., Gall, M.-A., Gylfadottir, S. S., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112010 · Cited by 12
Self-citationMicro and Macrovascular Complications in Diabetes Mellitus
Mohammed, S., Muhammed, H., Shetty, T. V., & Shanavas, S. (2025) · Yangtze Medicine · doi:10.4236/ym.2025.91009 · Cited by 15
A Study on Peripheral Neuropathy and Its Related Risk Factors Associated With hba1c Levels
Hossain, M., Sarkar, M., Mahbub, I., & Islam, S. (2021) · Journal of Bio-Science · doi:10.3329/jbs.v29i2.54961 · Cited by 14
“The vascular risk factors were found in develops DPN in Type-2 DM (Pop-Busui et al. 2013, Andersen et al. 2018, Callaghan et al. 2018).”
BackgroundPiliponienė, L., Veličkienė, D., & Kregždytė, R. (2021) · Medicina · doi:10.3390/medicina57121380 · Cited by 15
“Several studies observed lower DN indices: researchers in Greece [23] reported a cumulative incidence of DN of 30% during a 7 year-long observation and a Danish study reported a 10% cumulative incidence of DN during a 13 year-long study of the disease [24].”
BackgroundGlyoxalase I is a novel target for the prevention of metabolic derangement
Miranda, E. R., & Haus, J. M. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108524 · Cited by 11
An Overview on Diabetic Neuropathy
Singh, U., Sharma, R., & Kumar, R. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998295741240606104106 · Cited by 14
Dweib, M., & Sharif, N. E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216719 · Cited by 18
“Moreover, it is worth noting that diabetic peripheral neuropathy tends to be more prevalent in those with T2DM [13–18] than in T1DM [19], and after a duration of 5 to 10 years of diabetes, the incidence of peripheral neuropathy approximately increases twofold [20,21].”
BackgroundHuang, Y., Zheng, Z. J., Chen, H., & Gu, C. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01584-0 · Cited by 15
Liu, Y., Wu, D., Zheng, H., Ni, Y., Zhu, L., Jiang, Y., Dai, J., Sun, Q., Zhao, Y., Zhang, Q., et al. (2024) · Journal of Diabetes Research · doi:10.1155/2024/4538199 · Cited by 8
Cardiovascular autonomic and peripheral sensory neuropathy in women with obesity
Keller, N., Zádori, J., Lippai, B., Szöllősi, D., Márton, V., Wellinger, K., Lada, S., Szűcs, M., Menyhárt, A., Kempler, P., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1386147 · Cited by 13
Karakus, K. E., Aktürk, H. K., Snell‐Bergeon, J. K., & Shah, V. N. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251318740 · Cited by 14
Eid, S., Elzinga, S. E., Kim, B., Rumora, A. E., Hayes, J. M., Carter, A., Pacut, C. M., Allouch, A. M., Koubek, E. J., & Feldman, E. L. (2024) · Diabetes · doi:10.2337/db23-0997 · Cited by 11
Self-citationAnastasiou, G., Liberopoulos, E. N., Tentolouris, N., & Παπάνας, Ν. (2024) · The International Journal of Lower Extremity Wounds · doi:10.1177/15347346241240513 · Cited by 11
Yousuf, M. S., Moreno, M. M., Woodall, B. J., Thakur, V., Li, J., He, L., Arjarapu, R., Royer, D., Zhang, J., Chattopadhyay, M., et al. (2025) · Diabetes · doi:10.2337/db23-1025 · Cited by 11
Methylglyoxal Drives a Distinct, Nonclassical Macrophage Activation Status
Tsokanos, F., Muley, C., Khani, S., Hass, D., Fleming, T. H., Wolff, G., Bartelt, A., Nawroth, P. P., & Herzig, S. (2021) · Thrombosis and Haemostasis · doi:10.1055/s-0041-1726346 · Cited by 8
Self-citationGriggs, R. B., Nguyen, D. V. M., Yermakov, L. M., Jaber, J. M., Shelby, J. N., Steinbrunner, J. K., Miller, J. A., Gonzalez-Islas, C. E., Wenner, P., & Susuki, K. (2021) · eNeuro · doi:10.1523/eneuro.0201-21.2021 · Cited by 9
“Increased methylglyoxal concentration in the blood or serum of patients with type 2 diabetes (Andersen et al., 2018), Alzheimer’s disease (Haddad et al.”
BackgroundInfluentialXu, F., Zhao, L.-H., Wang, X.-H., Wang, C., Yu, C., Zhang, X., Ning, L.-Y., Huang, H., Su, J., & Wang, X. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00795-z · Cited by 8
“In addition, overproduction of metabolites of oxidative stress, such as myeloperoxidase, superoxide dismutase-3, thiobarbituric acid reactive substances (TBARS) and methylglyoxal, were improved to be with progression of diabetic neuropathy [34, 35].”
BackgroundKim, K., Lee, S. N., Ahn, Y., Ko, S., & Yun, J. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14063 · Cited by 8
Diabetic distal symmetric polyneuropathy: More than just “tingling in the feet”
Bell, D. S. H., & Jerkins, T. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70235 · Cited by 7
The intricacies of advanced glycation end products (AGEs) in diabetic neuropathy
Rao, W., Hussain, M. S., Naseem, N., & Siddiqui, W. A. (2025) · 3 Biotech · doi:10.1007/s13205-025-04652-4 · Cited by 9
“…quickly forms a reversible Schiff’s base, and it reorganizes to produce an Amadori product, which becomes AGEs 3 Biotech (2026) 16:24 States, Denmark, China, and the Netherlands have reported a high prevalence of obesity among neuropathic patients (Andersen et al. 2018; Callaghan et al. 2018).”
Screening for diabetic peripheral neuropathy at community pharmacies in Slovakia
Pagáčová, Z., Grofik, M., Fazekaš, T., Žufková, V., & Mináriková, D. (2024) · Croatian Medical Journal · doi:10.3325/cmj.2024.65.85 · Cited by 6
Genetic Variants Influence the Development of Diabetic Neuropathy
Hajdú, N., Rácz, R., Tordai, D. Z., Békeffy, M. Z., Vági, O. E., Istenes, I., Körei, A. E., Kempler, P., & Putz, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126429 · Cited by 8
“Nevertheless, in the ADDITION-Denmark cohort, methylglyoxal plasma levels were found to independently predict the incidence of DPN, with a hazard ratio of 1.46 (95% CI 1.12–1.89) [69].”
BackgroundInfluentialDiabetic Peripheral Neuropathy
Sharma, P. (2024) · Springer eBooks · doi:10.1007/978-981-97-9290-0_1 · Cited by 6
Racial and Ethnic Differences in Peripheral Neuropathy Risk Factors Among United States Adults
Reynolds, E. L., Russman, D., Elafros, M. A., Feldman, E. L., & Callaghan, B. C. (2025) · Neurology · doi:10.1212/wnl.0000000000213851 · Cited by 8
Self-citationPainful diabetic polyneuropathy: modern approaches to diagnosis and treatment
Ахмеджанова, Л. Т., & Mandra, E. V. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-23-86-92 · Cited by 7
Becker, A. K., Auditore, A., Pischetsrieder, M., Meßlinger, K., Fleming, T. H., Reeh, P. W., & Sauer, S. K. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.012890 · Cited by 8
“Recently, another study identified high levels of methylglyoxal as a relevant risk factor for the development of diabetic polyneuropathy (14).”
BackgroundSelf-citationWu, Y. H. A., He, J. H., McDermott, K. M., Wang, D., Fang, M., Windham, B. G., Selvin, E., & Hicks, C. W. (2025) · Journal of the American Geriatrics Society · doi:10.1111/jgs.70041 · Cited by 6
“PN has traditionally been associated with diabetes [1, 2, 31], but studies have shown it's also common in individuals without diabetes, with age as an independent risk factor [9, 33, 34].”
Neuropati Diabetes Sebagai Faktor Predisposisi Terjadinya Luka Pada Kaki
Sriyati, S. (2024) · Jurnal Ilmiah STIKES Yarsi Mataram · doi:10.57267/jisym.v14i1.336 · Cited by 5
He, Y., Ye, M., Shen, Z., Zhong, Z., Xia, Y. Y., & Li, Q. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.108950 · Cited by 5
Long-term complications of significant weight loss: lessons learned from bariatric surgery
Harrington, S., Kang, S., Telesca, L., COHEN, R. V., & le Roux, C. W. (2023) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2023.46 · Cited by 5
Early diagnosis and treatment of diabetic and alcoholic polyneuropathy in outpatient practice
Golovacheva, V. A. (2020) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2020-6-96-103 · Cited by 5
Meyer, A. R., García, G., Mikesell, A. R., O'Flanagan, S., Stucky, C. L., & Campbell, Z. T. (2025) · Pain · doi:10.1097/j.pain.0000000000003761 · Cited by 5
Anandan, C., Horak, H. A., Patel, K., & AANEM (2025) · Muscle & Nerve · doi:10.1002/mus.70015 · Cited by 5
Liu, Y., Wang, Y., Tian, X., Jiang, T., Tang, C., Zhu, L., Cui, W., Song, W., Ma, C., Song, S., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1626191 · Cited by 6
Maalmi, H., Nguyen, P., Strom, A., Bönhof, G. J., Rathmann, W., Ziegler, D., Menden, M. P., Roden, M., Herder, C., & GDS Group (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70009 · Cited by 5
Kryska, A., Sawic, M., Depciuch, J., Sosnowski, P., Szałaj, K., Paja, W., Khalavka, M., & Sroka‐Bartnicka, A. (2025) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2025.102804 · Cited by 4
A Systematic Review on Extracting Predictors for Forecasting Complications of Diabetes Mellitus
Erandathi, M., Wang, W. Y. C., & Mayo, M. (2021) · International Conference on Medical and Health Informatics (ICMHI) · doi:10.1145/3472813.3473211 · Cited by 6
“However, predicting the risk of CoDM is challenging because of the presence of confounders and the disputability of a standard set of features used by different researchers [5–7].”
BackgroundThe conundrum and enigma of painful and painless neuropathy
Røikjer, J., & Ejskjær, N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820669-0.00012-8 · Cited by 4
Maalmi, H., Herder, C., Huth, C., Rathmann, W., Bönhof, G. J., Heier, M., Köenig, W., Roden, M., Peters, A., Ziegler, D., et al. (2022) · International Journal of Obesity · doi:10.1038/s41366-022-01122-2 · Cited by 5
Jin, M., Liu, J., Liu, K., Zhao, Z., & Sun, S. (2023) · BMC Pediatrics · doi:10.1186/s12887-023-04323-4 · Cited by 4
“In this study, we found that the abnormal rates of SSR and NCS in the long duration of illness were higher than those in the short duration of illness, suggesting that pediatric DPN was related to the duration of disease, which has been confirmed in most adult living with diabetes [32, 33].”
BackgroundDebele, G. R., Abdisa, S., Kefeni, B. T., Geda, A., Jifar, W. W., Kitila, K. M., & Hajure, M. (2023) · Archives of Public Health · doi:10.1186/s13690-023-01202-3 · Cited by 5
“However, the finding is higher than studies conducted in Denmark and North West Ethiopia which was 10% and 16.63%, respectively [21, 29].”
BackgroundResultInfluentialPonirakis, G., Al‐Janahi, I., Elgassim, E., Hussein, R., Petropoulos, I. N., Gad, H., Khan, A., Zaghloul, H. B., Siddique, M. A., Ali, H. A., et al. (2024) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12664 · Cited by 5
Clinical Features of Diabetes Neuropathies
SLOAN, G. P., Pan, Q., Gao, L., Guo, L., & Tesfaye, S. H. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-15613-7_3 · Cited by 7
Potential predictive biomarker for diabetic peripheral neuropathy: serum neuron-specific enolase
Majeed, I. F., Baban, R., Salman, I. N., & Al-Rufaie, M. M. (2023) · Current Issues in Pharmacy and Medical Sciences · doi:10.2478/cipms-2023-0039 · Cited by 4
Association of serum magnesium level with small fiber neuropathy in patients with type 2 diabetes
Liu, X., & Hu, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1509820 · Cited by 3
Sebastião, R., Fonseca, P., Sousa, M., Machado, L. J., Sousa, F., Carvalho, D., Sacco, I. D. C. N., & Vilas-Boas, J. P. (2026) · Clinical Biomechanics · doi:10.1016/j.clinbiomech.2026.106806 · Cited by 3
Itani, M., Gylfadottir, S. S., Krøigård, T., Gaist, L. M., Holbech, J. V., Kristensen, A. G., Karlsson, P., Möller, S., Tankişi, H., Gaist, D., et al. (2022) · BMJ Neurology Open · doi:10.1136/bmjno-2021-000247 · Cited by 3
Self-citationSamartsev, I. N., Живолупов, С. А., Markova, M. N., & Chernoknizhnaya, S. S. (2024) · Medical alphabet · doi:10.33667/2078-5631-2024-2-26-32 · Cited by 3
Cutaneous Carbonyl Stress Is Associated With Nerve Dysfunction in Recent-Onset Type 2 Diabetes
Bönhof, G. J., Strom, A., Jung, T., Bódis, K. B., Szendroedi, J., Wagner, R. J., Grune, T., Roden, M., & Ziegler, D. (2024) · Diabetes Care · doi:10.2337/dc24-1799 · Cited by 3
Diabeteskomplikationen – Diabetes und Nervensystem
Meyhöfer, S., & Schmid, S. M. (2020) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1038-0102 · Cited by 4
“Des Weiteren ist die Abnahme und Kontrolle des Körpergewichts bei Personen mit T2DMessenziell [26].”
BackgroundComprehensive Factors for Predicting the Complications of Diabetes Mellitus: A Systematic Review
Erandathi, M., Wang, W. Y. C., Mayo, M., & Lee, C. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998271863231116062601 · Cited by 8
“Additionally, a significant association cannot be found between sex and incident DPN [13].”
BackgroundInfluentialCheng, M.-K., Guo, Y., Zhang, Z., Kang, X., Wang, D., Ren, H.-H., & Yuan, G. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2522970 · Cited by 2
“SBP, DBP, HDL, and LDL have been demonstrated to be closely associated with the progression of DPN [30].”
Qiao, Q., Cao, J., & Hou, X. (2025) · Translational Vision Science & Technology · doi:10.1167/tvst.14.9.29 · Cited by 2
“Given the documented associations between age and both corneal nerve parameters and DPN, 27,28 and considering the clinical accessibility of age data, we further developed a diagnostic model that incorporated age along with CNFD, CNBD, and CNFL.”
Xiang, H., Tang, Z., Zhang, X., Zhao, W., Chen, X., Zeng, Q., Li, X., Zhang, M., Cheng, S., Gao, R., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113218 · Cited by 2
Mechanisms of Nerve Injury in Diabetes: Dyslipidemia, Bioenergetics, and Oxidative Damage
Eid, S., Noureldein, M. H., Savelieff, M. G., & Feldman, E. L. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-15613-7_16 · Cited by 2
Self-citationSLOAN, G. P., Pena, P. D., Andag‐Silva, A., Cunanan, E. C., Jimeno, C., Robles, J. J., & Tesfaye, S. H. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14268 · Cited by 2
“…DPN are well known, and include diabetes-related factors, such as a longer duration of diabetes and a higher glycated hemoglobin (HbA1c; i.e., poorer diabetes con-trol), and other potentially modi fi able cardiovascular risk factors, such as dyslipidemia, obesity, hypertension and smoking 28,30 .”
BackgroundCao, B., Li, K., Ke, J., & Zhao, D. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s461330 · Cited by 2
“34,35 Although current research on RC and peripheral nerve damage is limited, a study has found that fluctuations in RC levels were associated with an increased risk of developing neuropathy.”
BackgroundHubungan Lama Menderita Diabetes Melitus Tipe 2 Dengan Kejadian Neuropati Diabetik
Mawaddah, M., & Wati, D. W. (2024) · Jurnal Lmu Farmasi dan Kesehatan/ · doi:10.59841/an-najat.v2i1.928 · Cited by 8
Kim, K., Oh, T. J., Park, Y. S., Chang, W., Cho, H. C., Lee, J., Lee, Y. K., Choi, S. H., & Jang, H. C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.881093 · Cited by 3
Pathogenesis and Treatment of Diabetic Peripheral Neuropathy
Kang, S. M. (2022) · Journal of Korean Diabetes · doi:10.4093/jkd.2022.23.4.222 · Cited by 2
Clinical Diagnosis of Diabetic Peripheral Neuropathy
Perkins, B. A., & Bril, V. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-15613-7_5 · Cited by 3
Characteristics and Treatment of Painful Diabetic Neuropathy
Gylfadottir, S. S., & Finnerup, N. B. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-15613-7_25 · Cited by 2
Self-citationDiabetic Polyneuropathy: from Pathogenesis to Pathogenetic Therapy
Tanashyan, M. М., State, F. S. A. E. I. O. H. E. ‘. M. S. F. M., Антонова, К. В., Спрышков, Н. Е., Панина, А. А., Лагода, О. В., & Shchukina, E. P. (2024) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2024-20-8-54-62 · Cited by 3
Pamungkas, R. A., Usman, A. M., & Chamroonsawasdi, K. (2023) · Indonesian Contemporary Nursing Journal (ICON Journal) · doi:10.20956/icon.v7i2.21689 · Cited by 2
Andrei, C., Șeremet, O. C., Pușcașu, C., & Zanfirescu, A. (2025) · Biomedicines · doi:10.3390/biomedicines13071709 · Cited by 5
“8 and TRPA1 channels, further increasing nociceptor sensitivity [58–61].”
Diabetic polyneuropathy: diagnosis, prevention, and treatment
Golovacheva, V. A., & Strokov, I. A. (2020) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2020-4-113-118 · Cited by 2
Causes and Implications of Isolated Small Fiber Neuropathy
Callaghan, B. C., & Singleton, J. R. (2021) · Neurology · doi:10.1212/wnl.0000000000012895 · Cited by 2
Self-citationWadhwa, H., & Misra, S. L. (2025) · Clinical and Experimental Optometry · doi:10.1080/08164622.2025.2499601 · Cited by 1
“9,10 These differences may explain why optimisation of specific risk factors reduce the development of neuropathy or nephropathy in one type of diabetes but not the other.”
Yang, P., Tseng, P., Chang, K., Chao, C., Wei, J., Yang, W., Chen, C., Ke, H., Lee, P., Chen, C., et al. (2025) · Obesity · doi:10.1002/oby.70012 · Cited by 1
Retinopathy, Neuropathy, and Foot Care
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch19 · Cited by 1
Diabetic neuropathy: Current issues in diagnosis and prevention
Spallone, V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00016-6 · Cited by 2
Gu, X., Zhu, F., Gao, P., Shen, Y. H., & Lu, L. (2025) · Journal of Health Population and Nutrition · doi:10.1186/s41043-025-00864-9 · Cited by 1
“PN was set as the primary endpoint in the ADDITION Denmark study [27].”
Treatment Options for Diabetic Neuropathy: Insights from the Romanian Neuropathy Guidelines
Nica, A. E., Parliteanu, O. A., Claudia, S., Dobjanschi, C. G., Rusu, E., & Radulian, G. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1009813 · Cited by 3
Metadata
- Authors
- Andersen, S. T., Witte, D. R., Dalsgaard, E.-M., Andersen, H., Nawroth, P., Fleming, T., Jensen, T. M., Finnerup, N. B., Jensen, T. S., Lauritzen, T., Feldman, E. L., Callaghan, B. C., & Charles, M.
- Affiliations
- Aarhus University (DK)
- Aarhus University Hospital (DK)
- University Hospital Heidelberg (DE)
- University of Michigan (US)
- Corresponding author
- Andersen, Signe T.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-02-27
- Volume
- 41
- Issue
- 5
- Pages
- 1068-1075
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2790769408
- Cited by
- 248
- References
- 41
- Citations by year
- 2026: 16 · 2025: 38 · 2024: 36 · 2023: 38 · 2022: 28 · 2021: 37 · 2020: 29 · 2019: 17 · 2018: 9
- FWCI
- 15.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Site cant be reached (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Funders
- Novo Nordisk (Novo Nordisk Foundation Challenge Programme grant)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetic Foot Ulcer Assessment and Management
- Keywords
- diabetic polyneuropathy, type 2 diabetes, risk factors, Michigan Neuropathy Screening Instrument, methylglyoxal, HDL cholesterol, LDL cholesterol, waist circumference, body mass index, age, weight, diabetes screening, primary care, neuropathy prevention, intensive diabetes treatment, cumulative incidence, long-term follow-up
- MeSH terms
- Aged, Denmark, Diabetes Mellitus, Type 2, Diabetic Neuropathies, Female, Follow-Up Studies, Humans, Male, Mass Screening, Middle Aged, Obesity, Primary Health Care, Risk Factors, Cohort Studies, Incidence, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.